Business Wire

BITFURY-GROUP

4.11.2021 13:02:08 CET | Business Wire | Press release

Share
Bitfury Appoints Former United States Acting Comptroller of the Currency Brian P. Brooks Chief Executive Officer

Bitfury Group (“Bitfury” or the “Company”), the Bitcoin mining and crypto tech pioneer, today announced that Brian P. Brooks, former United States Acting Comptroller of the Currency, has joined the Company as Chief Executive Officer, effective October 29, 2021. Mr. Brooks will lead the 10-year-old crypto unicorn as it launches a new funding round, increases the growth of its mining business with a revolutionary new microchip design and new global data center locations, and scales a portfolio of innovative businesses that grew out of the Company’s heritage as an early Bitcoin leader. Valery Vavilov, Founder of Bitfury, will become Chairman of the Board of Directors and Chief Vision Officer, where he will continue his focus on developing over-the-horizon hardware and software innovations for Bitfury as it builds the infrastructure for a tokenized global economy.

Mr. Vavilov said, “Since our founding, Bitfury has pioneered innovative blockchain hardware and software infrastructure, and today represents a comprehensive platform addressing and enhancing the full digital asset value chain. With an eye toward the next phase in our evolution, we are thrilled to welcome Brian to the Company. Brian is a respected executive and thought leader with deep regulatory, digital asset and capital markets expertise who shares Bitfury’s vision for a decentralized peer-to peer economy. Together, we will continue to execute Bitfury’s growth strategy and help businesses, governments, organizations, and individuals leverage the blockchain to solve the most pressing challenges of today and tomorrow.”

Since its inception in 2011, Bitfury has developed into a full-service blockchain technology company and one of the world’s leading providers of large-scale digital asset infrastructure solutions. Bitfury’s platform of emerging technologies businesses includes its self-mining operations, with seven ultra-low-cost energy sites globally alongside its new United-States based Cipher Mining subsidiary; hardware products for high-performance computing needs, including seven generations of its own specialized micro-chips and next generation immersion cooling systems; and software and enterprise blockchain solutions spanning security, payments, and applications for the creator economy, among others.

Mr. Brooks said, “Bitfury is an established leader in the digital asset industry, renowned for its sustained research and development efforts and best-in-class proprietary technologies. As the adoption of – and use cases for – Bitcoin, other cryptoassets, and their underlying blockchains continues to accelerate worldwide, the Company’s diversified portfolio has immense opportunity and is well positioned for long-term success. I look forward to working alongside Valery and Bitfury’s highly experienced leadership team to grow the Company’s core businesses and scale its portfolio of new innovations.”

Brian P. Brooks Biography

Most recently, Mr. Brooks served as Chief Executive Officer of digital asset exchange and marketplace Binance.US. Previously, from May 2020 to January 2021, Mr. Brooks served as the Acting Comptroller of the Currency, where he was the administrator of the federal banking system and the chief executive of the 3,500-employee federal agency responsible for chartering and supervising banks comprising 70 percent of all banking activity in the United States. He also served as a member of the board of directors of the Federal Deposit Insurance Corporation and a voting member of the Financial Stability Oversight Council. Often referred to in the media as “the first fintech Comptroller” and “CryptoComptroller” for his work advancing financial innovation, Mr. Brooks led the government’s efforts to provide regulatory clarity for stablecoins, digital asset custody, and the development of blockchain payment networks, and granted the first federal bank charter to a cryptocurrency company. He also launched Project REACh, a national partnership of civil rights organizations, tech companies, and banks to promote financial inclusion through greater access to credit and capital.

From 2018 to 2020, Mr. Brooks served as Chief Legal Officer of Coinbase Global, Inc., where he led legal, compliance, internal audit, government relations, and global investigations groups at the digital asset platform. From 2014 to 2018, he served as Executive Vice President, General Counsel, and Corporate Secretary of Fannie Mae, a $3.2 trillion asset public company that is the world’s largest investor in single-family and multifamily mortgage assets, and from 2011 to 2014, as Vice Chairman of OneWest Bank, N.A. Before joining OneWest Bank, N.A., he served as managing partner of O’Melveny & Myers LLP’s Washington, D.C. office.

Mr. Brooks also serves as an adviser or board member for a number of financial and fintech companies. Mr. Brooks received his BA from Harvard University and his JD from the University of Chicago.

About Bitfury Group

Bitfury Group is the world's leading technology company unlocking the full value chain of Bitcoin and other digital assets. Bitfury™ has built on its heritage as one of the earliest Bitcoin miners and developers of mining equipment to create solutions for the future – solutions such as the Crystal™ Blockchain advanced analytics platform, which helps law enforcement and private sector clients make cryptoassets safer and more compliant; the Liquidstack immersion cooling business, which dramatically reduces data center energy usage and makes Bitcoin mining and high performance computing more environmentally sustainable; Axelera AI, which unlocks the potential of artificial intelligence with the world’s most advanced AI technologies; Surround, providing blockchain-based solutions for the creator economy including digital rights management, payments, and NFT support; and others. Our mission is to make the world more secure and trusted by innovating at every level of technology – hardware, security, and software – to put trust back into the equation. To learn more, visit www.bitfury.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye